Subscribe to our Newsletter Abonnez-vous à notre newsletter
By subscribing to our Newsletter you will receive Sernova’s press releases and news as they develop by email. We do not send direct mail, customized online advertising, and we do not share your personal information. We respect your privacy. En vous abonnant à notre newsletter, vous recevrez par e-mail les communiqués de presse et les actualités de Sernova au fur et à mesure de leur développement. Nous n'envoyons pas de publipostage, de publicité en ligne personnalisée et nous ne partageons pas vos informations personnelles. Nous respectons votre vie privée.
Please read our Pour plus d’informations, veuillez lire notre Privacy policypolitique de confidentialité.
Press Release Communiqué de presse - September 14, 2023 14 September, 2023
Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 14, 2023 – Sernova Corp. (TSX:SVA)
(OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced
it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m.
Eastern Time. The call will now occur on September 22 at 10 a.m. Eastern Time. The business strategy and
update call remains as scheduled for October 5, 2023.
This call will introduce the newly appointed CEO, Cynthia Pussinen, as well as the recently appointed Chief
Business Officer, Dr. Modestus Obochi, Ph.D., MBA, and will discuss the overall vision of both executives to
deliver novel medical therapies to patients.
CEO Introduction:
Date: Friday, September 22, 2023
Time: 10:00 a.m. Eastern Time
Dial-In: 1-877-704-4453
Conference ID: 13741199
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1634340&tp_key=29a41cab17
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune
protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment in
the body for long-term survival and function of therapeutic cells that release essential factors that are absent or
deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated
its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University
of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to
shield therapeutic cells from immune system attack with the goal to eliminate the need for chronic, systemic
immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop
an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This
partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of
patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress two additional
development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid disease resulting from
thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
Tel: 619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Press Release Communiqué de presse - September 13, 2023 13 September, 2023
Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
- Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus
Obochi, on September 15, 2023 -
- Business Update, Strategy & Outlook Call on October 5, 2023 -
LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 13, 2023 – Sernova Corp. (TSX:SVA)
(OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced
it will host two investor and analyst conference calls, with corresponding live webcasts.
The first of these two events will introduce the newly appointed CEO, Cynthia Pussinen, as well as the recently
appointed Chief Business Officer, Dr. Modestus Obochi, Ph.D., MBA, and will discuss the overall vision of both
executives to deliver novel medical therapies to patients. The second in this series of calls is intended to
provide an overall business update and discuss the strategy and operating plans going forward. Details of each
event are as follows:
CEO Introduction:
Date: Friday, September 15, 2023
Time: 10:00 a.m. Eastern Time.
Dial-In: 1-877-704-4453
Conference ID: 13741199
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1634340&tp_key=29a41cab17
Business Update:
Date: Thursday, October 5, 2023
Time: 10:00 a.m. Eastern Time.
Dial-In: 1-877-704-4453
Conference ID: 13741177
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1634043&tp_key=195a900d23
The October 5 event will conclude with a question-and-answer component, and investors can also email
questions in advance to info@sernova.com. The company will answer as many questions as allowable within
the given time constraints. Subsequently, replays of each event will be available on the events section of the
Company’s website at www.sernova.com.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune
protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment
in the body for long-term survival and function of therapeutic cells that release essential factors that are absent
or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has
demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study
at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the
University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need
for chronic, systemic immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic
partnership to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet
replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing
cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to
progress two additional development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid
disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
Tel: 619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Press Release Communiqué de presse - September 07, 2023 7 September, 2023
Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device
Dr. Alice Tomei of the University of Miami, Miller School of Medicine, to present updates in podium
presentation at the 2023 IPITA-IXA-CTRMS Joint Congress being held in San Diego from October 26-29
LONDON, Ontario; WINDHAM COUNTY, Connecticut – September 7, 2023 – Sernova Corp. (TSX:SVA)
(OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today provided a
development update on its exclusively licensed, proprietary conformal coating immune protection technology,
being advanced in combination with the Cell Pouch™ through a collaboration with Dr. Alice Tomei at the
University of Miami, Miller School of Medicine. The goal of the technology is to eliminate the need for long-
term use of conventional immunosuppressive medications currently required to prevent graft rejection with
Sernova’s flagship cell therapy program for treatment of type 1 diabetes (T1D).
“One of the biggest challenges in bringing a ‘functional cure’ to people living with T1D is preventing therapeutic
cell transplantation from eliciting an immune response without the need for conventional life-long
immunosuppressive agents,” said Dr. Philip Toleikis, Chief Technology Officer of Sernova Corp. “Our conformal
coating technology closely surrounds insulin-producing islets without altering the genetic makeup or function,
offering potential protection from the human immune system while maintaining normal cell function. We are
encouraged by both our ongoing preclinical results, and our continued progress with manufacturing scale-up of
conformally coated islets, which is a key hurdle prior to initiation of clinical studies.”
The conformal coating technology has been developed in partnership with Dr. Alice Tomei, Miami Engineering
Career Development Associate Professor of Biomedical Engineering at the University of Miami and director of
the Islet Immunoengineering Lab at the Miller School of Medicine Diabetes Research Institute. Dr. Tomei will
provide a detailed update of the technology in a podium presentation at the 2023 IPITA-IXA-CTRMS Joint
Congress being held in San Diego from October 26-29. Presentation details will be shared in October 2023.
Dr. Tomei added, “I am pleased with the technical advancements we have made in collaboration with the
Sernova scientific team. We have achieved success in pre-clinical safety and efficacy studies demonstrating the
optimal conditions for conformally coated islets within the Cell Pouch. We have also made significant progress
in developing release criteria which are essential for the clinical manufacturing process. Furthermore, along
with Sernova, we have optimized the manufacturing process and are currently scaling up the GMP production
of the conformally coated islets. These elements are critical to advancing the conformal coating technology
into the clinic for the potential treatment of all patients with T1D. I look forward to sharing more on our
progress at the 2023 IPITA-IXA-CTRMS Joint Congress in San Diego.”
Pre-clinical studies conducted at the University of Miami in collaboration with Sernova demonstrated that
conformally coated islets transplanted into the pre-vascularized Cell Pouch achieved normal blood glucose
control and reversed the effects of T1D in a syngeneic rat model of T1D. Conformally coated islets show
normal responsiveness to glucose and fully regulated insulin production when transplanted in the Cell Pouch.
Treated animals ultimately achieved full insulin independence (return to normal glucose levels).
In optimization studies in T1D animal models transplanted with conformally coated allogeneic islets in an
implanted Cell Pouch, subjects treated with a single selective immune response agent achieved sustained,
normalized blood glucose levels during the study period. These findings support our approach and the
potential to eliminate the need for the immunosuppressive cocktails that are typically used for islet transplant
patients and are frequently associated with toxic side effects.
As prerequisites for clinical testing in humans, characterization assays have been identified to develop and
validate product release criteria for conformal coating. Long-term in vitro stability and durability studies have
been successfully completed and release testing is routinely conducted for the finished coated islet product to
ensure quality, safety, and efficacy potential, prior to the transplantation of conformally coated islets into Cell
Pouch. Sernova is also undertaking a standard array of biocompatibility studies and is completing an allogeneic
optimization study using conformally coated islets in the Cell Pouch with the addition of a selective immune
response agent which has proven effective in the ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in
T1D at the University of Chicago. A single agent provided intermittently with the conformal coating technology
would be a significant advancement in the field of cellular immune protection.
Additionally, through a design and manufacturing partner, Sernova is developing a bench-top, scalable, fully
automated, and GMP-compatible cell coating system. The clinical-scaled system is designed for installation in
GMP cell manufacturing facilities that produce coated islets for clinical trials.
ABOUT THE CONFORMAL COATING TECHNOLOGY
The conformal coating technology is a proprietary, mechanically stable, thin, biocompatible, and cross-linked
polymer hydrogel that coats the outside of each individual islet housed within the Cell Pouch. The conformal
coating technology offers selective permeability, with immuno-protective capability, while not interfering with
the kinetics of insulin and glucose release. Importantly, the conformal coating configuration also allows for the
physiological transfer of oxygen and nutrients needed for islet survival and long-term function within the pre-
vascularized Cell Pouch.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune
protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment
in the body for long-term survival and function of therapeutic cells that release essential factors that are absent
or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has
demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study
at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the
University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need
for chronic, systemic immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic
partnership to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet
replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing
cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to
progress two additional development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid
disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
Tel: 619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Press Release Communiqué de presse - September 05, 2023 5 September, 2023
Sernova Corporation Announces the Appointment of Cynthia Pussinen as CEO
Industry veteran with deep commercial experience joins to lead the next stage of growth and development
Dr. Philip Toleikis will serve as Chief Technology Officer
Sernova to host investor calls
LONDON, Ontario; Windham County, CT – September 5, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF)
(FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that its Board of
Directors has appointed Cynthia Pussinen as Chief Executive Officer and a member of the Board of Directors.
Dr. Philip Toleikis, who has led the company since 2009 as President and CEO will serve as Chief Technology
Officer.
Ms. Pussinen’s expertise spans the drug development continuum from research through commercialization. She
has led the development, licensure, commercialization and/or subsequent delivery to patients, of more than
fifteen new medical therapies for patients globally, including Obizur® (Antihemophilic Factor (Recombinant),
Porcine Sequence), Eraxis® (anidulafungin), Zmax® (azithromycin extended-release) and LUXTURNA®
(voretigene neparvovec-rzyl), the first gene therapy approved in both the United States and the European
Union.
Most recently, Ms. Pussinen was the Chief Technical Officer for Spark Therapeutics, Inc., a fully integrated,
commercial gene therapy company, and a member of the Roche Group. Prior to joining Spark in 2021, Ms.
Pussinen’s leadership roles include 6 years with Ipsen Biomeasure and Ipsen Biosciences, U.S. R&D focused
subsidiaries of Ipsen, where she served as President and CEO. She was instrumental in leading and executing
the divestiture of Obizur® and its associated manufacturing physical infrastructure to Baxter. Ms. Pussinen was
also the Executive Vice President, Technical Development, Operations & Supply Chain for Actinium
Pharmaceuticals, Inc. and the Global Vice President and General Manager, Life Sciences and Specialty
Chemicals for Honeywell International. Early in her career Ms. Pussinen spent more than 18 years at Pfizer in a
variety of increasingly responsible leadership roles across various functional areas.
Ms. Pussinen also served on the Drexel University Solutions Advisory Board, as a Board Director for Spark
Therapeutics UK Ltd. and Spark Therapeutics Ireland Ltd. and is a member of an early-stage biotech
company’s scientific and technical advisory board.
Ms. Pussinen earned a Master of Science in R&D management from Rensselaer Polytechnic Institute and a
Bachelor of Science in chemistry, with a minor in engineering from the University of Connecticut. She is lean six
sigma certified, is recognized as a mentor through the Healthcare Businesswomen’s Association (HBA) and was
honored by WEST (Women in the Enterprise of Science and Technology) as a recipient of their Giving Back
award.
“Sernova has demonstrated tremendous growth over the past several years as it has transitioned from a
research company to one that is moving towards commercialization of a product for the treatment of multiple
chronic diseases including our flagship program for Type 1 Diabetes (T1D). As a united Board, we feel now is
the time to bring in an industry leader with extensive experience with large pharmaceutical companies as well
as entrepreneurial biotech and advanced therapeutics focused companies,” commented Brett Whalen, Chair of
the Board of Directors of Sernova. “The skills that Ms. Pussinen brings to our company include over 25 years
of global experience shepherding new therapies from development through commercialization across multiple
conditions with sales measured in the billions.”
Mr. Whalen continued, “the Board would like to thank Dr. Toleikis for his significant contributions to Sernova
and his passionate commitment to our mission, and for continuing in his new role as Chief Technology Officer.
Under his leadership, Sernova has solidified the strong scientific and technical foundations for future success
and created significant market value driven by the strong positive clinical data outcomes in T1D. The Board is
convinced that Ms. Pussinen and Dr. Toleikis bring the right combination of experience and talent to optimize
this unique opportunity for all stakeholders.”
Ms. Pussinen added, “It is an honor and a privilege to join Sernova at this pivotal stage in the company’s
evolution. Sernova has developed novel technology, and I am very excited by the positive pre-clinical and
clinical results thus far. The company is a pioneer in creating new ways to address some of the most
challenging chronic diseases, providing the possibility of a life-changing ‘functional cure’ for conditions
including Type 1 Diabetes. I am inspired by the mission to improve human health and look forward to working
with the passionate Sernova team to boldly advance the company’s mission for the benefit of all patients,
stakeholders and investors.”
Dr. Toleikis said, “I am grateful to have led Sernova’s dedicated team over the past years. I am proud of all that
we have accomplished together over the past years, including establishing a strong technology and scientific
foundation along with introducing new treatments options to patients with chronic conditions. I am very
pleased to welcome Ms. Pussinen to the Sernova team as the new CEO and look forward to working together. I
look forward to my continued involvement with the Company to see through the realization of Sernova’s
mission to bring a functional cure to patients around the world suffering from chronic diseases.
Sernova’s management will host investor calls, firstly to introduce Ms. Pussinen, and later, in approximately 30
days, to provide an overview of Sernova as well as a question-and-answer session. Investors will be informed
of the details once finalized.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune
protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment
in the body for long-term survival and function of therapeutic cells that release essential factors that are absent
or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has
demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study
at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the
University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need
for chronic, systemic immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic
partnership to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet
replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing
cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to
progress two additional development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid
disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
Tel: 619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Press Release Communiqué de presse - July 26, 2023 26 July, 2023
Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph.D., MBA, as Chief Business Officer
LONDON, Ontario – July 26, 2023 – Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-
stage company and leader in cell therapeutics, today announced the appointment of Modestus Obochi, Ph.D.,
MBA, a veteran dealmaker and strategic leader with 25+ years of biotech and pharmaceutical industry
experience, as Chief Business Officer effective September 8, 2023.
“Dr. Obochi brings additional invaluable industry acumen to our expanding leadership team,” said Dr. Philip
Toleikis, President and Chief Executive Officer of Sernova. “His proven expertise in strategy, business
development, product lifecycle management, and operational excellence will be vital to our team as we
continue to strategically advance our proprietary therapeutic cell therapy technologies including our Cell Pouch
System™, both independently and with industry partners, as a potential ‘functional cure’ for multiple chronic
diseases.”
Dr. Obochi added, “I am very excited by the significant commercial potential and the immense clinical potential
that Sernova’s proprietary cell therapy platform has shown in the ongoing Phase 1/2 study in people living with
type 1 diabetes. As an immunologist and someone whose family has been impacted by the devastating effects
of T1D, the Sernova opportunity is very personal to me. I look forward to working with Sernova’s management
and board of directors, its partners, and research collaborators as we aim to develop Sernova’s proprietary cell
therapy platform into a commercially viable ‘functional cure’ modality for multiple chronic diseases, including
insulin-dependent diabetes, hemophilia A, and hypothyroidism.”
Based in the Chicago, Illinois area, where he has resided for the last 16 years, Dr. Obochi joins Sernova from
Phlow Corp., where he served as Executive Vice President of Strategy and Business Development. In that role,
he led the design, development, and execution of corporate strategy and business development plans. He also
managed the due diligence, structuring, and negotiations of all transactions, including licensing deals, product
acquisitions, partnerships, M&A, and strategic investments. Prior to his role at Phlow Corp., Dr. Obochi held
several executive-level commercial and business development roles at leading pharmaceutical companies
including Pfizer, Hospira, and Baxter International, and has previously consulted for several biotechnology
companies. Most notably, in these roles, Dr. Obochi has helped corporations raise significant capital and has
successfully structured and closed multiple strategic transactions worth over $5 billion. Dr. Obochi holds a
Ph.D. in Immunology from the University of British Columbia, Vancouver, and an MBA from the Beedie School
of Business of Simon Fraser University, Vancouver. He has published over 30 manuscripts, including journal
articles and symposia abstracts, and is an inventor on several patents, including one on cell transplantation.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable
medical device with immune protected therapeutic cells. On implantation, The Cell Pouch forms a natural
vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release
essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s
Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing
Phase 1/2 clinical study at the University of Chicago. Sernova is also advancing a proprietary technology in
collaboration with the University of Miami to shield therapeutic cells from immune system attack with the goal
to eliminate the need for chronic, systemic immunosuppression. In May 2022, Sernova and Evotec entered into
a global strategic partnership to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells)
based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-
producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova
continues to progress two additional development programs that utilize its Cell Pouch System: a cell therapy
for hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral factor VIII gene therapy
for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
Tel: 619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances, or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Press Release Communiqué de presse - June 26, 2023 26 June, 2023
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions
• In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined
islet transplants achieved insulin-independence for ongoing periods of 6 to 38 months.
• Following islet transplants to the 8-channel Cell Pouches, patients in the first cohort required only modest
islet top-up via portal vein to achieve insulin independence, supporting the contribution to blood glucose
control from islet grafts in the Cell Pouch™.
• Five of the 7 planned patients have been enrolled in the second cohort and implanted with higher capacity
10-channel Cell Pouches. Three patients in the second cohort have received their first pancreatic islet
transplant to Cell Pouch.
• Persistent fasting and stimulated serum C-peptide confirms stable islet graft function in the first evaluable
patient to receive islet transplants to the higher capacity Cell Pouch.
LONDON, Ontario – June 26, 2023 – Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-
stage company and leader in cell therapeutics, today announced updated positive interim data from its ongoing
Phase 1/2 clinical trial of the Cell Pouch System in patients with type 1 diabetes (T1D) and severe hypoglycemia
unawareness. The new data from the study, which is being conducted by Piotr Witkowski, M.D., Ph.D., at The
University of Chicago, were presented during an oral podium presentation at the American Diabetes
Association (ADA) 83rd Scientific Sessions, on June 24th, 2023 in San Diego, California.
The presentation discussed the first eleven patients enrolled across two cohorts in the clinical trial evaluating
Cell Pouch in combination with pancreatic islets and reconfirmed the safety of Cell Pouch up to more than 4
years following implant. During the trial, the function of the transplanted islets are measured by blood glucose
levels, patient insulin usage, and serum C-peptide - a measure of islet insulin secretion.
To date, 5 patients in the first cohort of 6 subjects who have completed Cell Pouch implantation, islet
transplant to Cell Pouch, and supplemental portal vein islet infusion, continue to experience insulin
independence for periods ranging from 6 months to greater than 3 years. The sixth patient in the first cohort
has only recently completed the protocol-defined islet transplants and awaits assessment of their islet graft
function.
In addition, updates were provided for the second cohort with the recently implemented 10-channel Cell Pouch
with more than 50% greater transplant capacity than the previous 8-channel system. Five of 7 patients meeting
the trial eligibility criteria have been enrolled in the second cohort and implanted with the higher capacity Cell
Pouch. Three of the 5 patients enrolled in the second cohort have each received a first islet transplant to their
implanted Cell Pouches. The first evaluable patient in the second cohort has demonstrated persistent fasting
and stimulated serum C-peptide levels following a single islet transplant into the pre-vascularized 10-channel
Cell Pouch.
KEY POINTS FROM THE INTERIM CLINICAL UPDATE
• Long-term surgical implantation of the Cell Pouch continues to be well tolerated with a favorable safety
profile in patients receiving either 8 or 10-channel Cell Pouches.
• Five of 6 patients in the first cohort achieved insulin independence following supplemental islet transplants
via the portal vein that were below the typical intraportal islet dose, indicating that islet graft function in the 8-
channel Cell Pouch is supporting ongoing glucose control.
• Histological assessment of sentinel Cell Pouches excised at ≥90 days post-transplant revealed surviving
functional islets in 5 of 6 patients in the first cohort.
• The 5 patients in the first cohort that have achieved insulin independence have each remained free of
endogenous insulin therapy ranging from 6 months to greater than 3 years. The sixth patient in the first cohort
has recently completed the protocol-defined islet transplants and is awaiting their next islet graft assessment.
• In the second cohort, 5 of 7 planned patients are now enrolled and implanted with the higher capacity Cell
Pouches. Three of the 5 patients have received their first dose of pancreatic islets transplanted to Cell Pouch.
• One patient in the second cohort has demonstrated persistent serum C-peptide levels after only a single
islet transplant into 10-channel Cell Pouch. The first patient in the second cohort developed persistent
neutropenia requiring cessation of immunotherapy. The third patient awaits their first islet graft assessment.
Further data from the second cohort of the clinical trial is expected in the second half of 2023.
“We are very pleased to see these positive data for our T1D trial with Cell Pouch, and especially our 10-
channel Cell Pouch configuration, as we pursue a ‘functional cure’ for patients with T1D,” said Dr. Philip
Toleikis, President and Chief Executive Officer of Sernova. “These additional data continue to confirm our
understanding and provide verification of our estimates of islet dose thresholds and density required for
optimal efficacy in this patient population. We continue to follow through on our commitment to rapidly enroll
the study’s second cohort, while setting the stage for Cell Pouch in combination with Evotec’s iPSC derived
islet-like clusters in our upcoming clinical trial.”
Dr. Piotr Witkowski, Director of the Pancreatic and Islet Transplant Program at The University of Chicago, and
principal investigator of the clinical trial added, “I continue to be encouraged by the results achieved in this
trial, and especially by the ease of use and favorable response from a single islet transplant to the larger Cell
Pouch. I look forward to reporting further data later this year.”
For more information on the ongoing clinical study, go to clinicaltrials.gov (NCT03513939).
To add to the ongoing Phase 1/2 clinical trial of the Cell Pouch System in T1D, Sernova also continues to
advance its global strategic partnership with Evotec SE (Evotec). Together the companies remain on track to
advance Sernova’s Cell Pouch in combination with Evotec’s induced pluripotent stem cell (iPSC) derived islet-
like clusters into the clinic. Furthermore, Sernova is advancing its conformal coating cellular immune
protection technologies in collaboration with the University of Miami with the goal to reduce or eliminate the
need for immunosuppression agents.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune
protected therapeutic cells. On implantation, the Cell Pouch forms a natural vascularized tissue environment in
the body for long-term survival and function of therapeutic cells that release essential factors that are absent
or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has
demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study
at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the
University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need
for chronic, systemic immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic
partnership to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet
replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing
cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to
progress two additional development programs that utilize its Cell Pouch System: a novel therapy for
hypothyroid disease resulting from thyroid gland removal and an ex vivo lentiviral factor VIII gene therapy for
hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
Tel: 619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances, or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Press Release Communiqué de presse - June 22, 2023 22 June, 2023
Sernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessions
Company to host in-person only analyst and investor event at an offsite location following the presentation on
Saturday, June 24 at the ADA Scientific Sessions
LONDON, Ontario – June 22, 2023 – Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-
stage company and leader in cell therapeutics, will be presenting updated interim data from its ongoing Phase
1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) and hypoglycemia
unawareness at the American Diabetes Association (ADA) 83rd Scientific Sessions, to be held June 23-26, 2023,
in San Diego.
The abstract, which was submitted several months ago, written by Dr. Piotr Witkowski, M.D., Ph.D. and his
team at The University of Chicago Pritzker School of Medicine, was released by the ADA and shows that five of
the six patients receiving the Sernova Cell Pouch remain insulin independent (>2.5 years, >1 year, 10 months, 2
months, and 1 month). With the 6th patient awaiting a final protocol-mandated islet transplant. The oral
podium presentation will contain additional updated information and will take place on Saturday, June 24. In
alignment with the ADA embargo policy, the additional data updates will be shared by Sernova following the
completion of the presentation. The abstract for the oral presentation can be accessed here.
Presentation details:
• Abstract: #240-OR
• Title: Islet Allotransplantation into Pre-vascularized Sernova Cell Pouch—Early Results from the University
of Chicago
• Abstract Session: Clinical Islet-Cell Transplantation
• Date: Saturday, June 24, 2023
• Time: 5:15 PM PT
• Location: Room 30
• Authors: Mateusz Ogledzinski, Sarah Gondek, William Lin, Kamila Milejczyk, Braden Juengel, Lisa Potter,
Piotr K. Bachul, Lindsay Basto, Laurencia Perea, Lingjia Wang, Martin Tibudan, Rolf Barth, John Fung, Piotr
Witkowski
Sernova will host an in-person analyst and investor event following the presentation at ADA:
• Date: Saturday, June 24, 2023
• Time: 6:30 PM PT
• Location: The Hilton San Diego Bayfront
• Room: Aqua 310B
Register for the event here: https://events.r20.constantcontact.com/register/eventReg?
oeidk=a07ejsjhyfz2e580299&oseq=&c=&ch=
Abstracts for the ADA 83rd Scientific Sessions can be accessed here:
https://eppro02.ativ.me/src/EventPilot/php/express/web/planner.php?id=ADA23
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune
protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment in
the body for long-term survival and function of therapeutic cells that release essential factors that are absent or
deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated
its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University
of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to
shield therapeutic cells from immune system attack with the goal to eliminate the need for chronic, systemic
immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic partnership to develop
an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet replacement therapy. This
partnership provides Sernova a potentially unlimited supply of insulin-producing cells to treat millions of
patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress two additional
development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid disease resulting from
thyroid gland removal and an ex vivo lentiviral factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
Tel: 619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances, or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Press Release Communiqué de presse - June 16, 2023 16 June, 2023
Sernova to Participate in Upcoming Truist Securities Cell Therapy Symposium
LONDON, Ontario – June 16, 2023 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-
stage company and leader in cell therapeutics, today announced it will be participating in the upcoming
symposia-cel Truist Securities Cell Therapy Symposium being held June 27, 2023 in New York City. Company
management will also be participating in one-on-one investor meetings at the conference.
symposia-cel - A Truist Securities Cell Therapy Symposium
Format: Fireside Chat
Date: June 27, 2023, 2:15pm
Participant: Dr. Philip Toleikis, President & CEO, Sernova Corp
Location: Lotte New York Palace
Please contact your representative at Truist to schedule a one-on-one meeting with the management team
during the conference.
ABOUT SERNOVA CORP. AND THE CELL POUCH SYSTEM™ PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes
with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune
protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment
in the body for long-term survival and function of therapeutic cells that release essential factors that are absent
or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has
demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study
at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the
University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need
for chronic, systemic immunosuppression. In May 2022, Sernova and Evotec entered into a global strategic
partnership to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells) based islet
replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-producing
cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to
progress two additional development programs that utilize its Cell Pouch System: a cell therapy for hypothyroid
disease resulting from thyroid gland removal and an ex vivo lentiviral factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Corporate:
Christopher Barnes
VP, Investor Relations
Sernova Corp.
christopher.barnes@sernova.com
Tel: 519-902-7923
www.sernova.com
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
Tel: 212-915-2577
Media:
Hannah Holmquist
LifeSci Communications
hholmquist@lifescicomms.com
619-723-4326
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but
not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects",
"potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should"
occur are used to identify forward-looking statements. These statements reflect management’s beliefs with
respect to future events and are based on information currently available to management on the date such
statements were made. Many factors could cause Sernova’s actual results, performances or achievements to
not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such factors could include, but are not limited to,
the company’s ability to secure additional financing and licensing arrangements on reasonable terms, or at all;
ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch System and/or
related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory
approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute
its business strategy and successfully compete in the market; and the inherent risks associated with the
development of biotechnology combination products generally. Many of the factors are beyond our control,
including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult
the company’s quarterly and annual filings available on www.sedar.com for additional information on risks and
uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or
obligation to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise.
Privacy PolicyPolitique de confidentialité
Updated July 6, 2018
Please read this Policy carefully along with our Legal Notice that describes our Terms of Use for the Website.
By accessing www.sernova.com (the “Website”) you hereby agree with the practices described in this Privacy Policy (the “Policy”)
This Policy applies to all information gathered through the Website and/or any related marketing technique or events.
Information Collection
The information collected is limited to the information that you decide to share with us through the News Dispatch Service, when participating at event or activities or in the general course of business by expressing an interest in obtaining information about Sernova Corp. and our products, such as name, email, phone number, and similar contact information. This information is stored through MailChimp (please refer to MailChimp Privacy Policy at https://mailchimp.com/legal/privacy/).
Information Sharing
Sernova Corp. is the sole owner of any information collected on the Website. We do not sell, share or rent this information to others.
Traffic and Automatic Information Collection
Sernova Corp. maintains log files of the traffic on www.sernova.com. This information is not linked to any personal information that you have provided us. Logs are used to manage traffic, identify content accessed, and IT requirements. Information logged and automatically collected includes without being limited to IP addresses and browser types. This information does not reveal your specific identity.
Cookies
Cookies can be used to provide you with a more personalized experience. The Website may use cookies to make that experience more companionable when you return to the Website. You have the option at all time to decline the use of cookies. If you choose to do so, you may not be able to fully use all features of the Website. You can also delete cookie files at all time from your computer. Those cookies may include first-party cookies (such as the Google Analytics cookies).
Updates
This Policy is a living document and may be amended or updated from time to time without further notice. We encourage you to review the Policy periodically.
Contact
If you have any questions or comments about our policy, you can email us at info@sernova.com or by phone at 1(877) 299-4603 or by mail at
Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8
Mis à jour le 6 juillet 2018
Veuillez lire attentivement cette politique ainsi que notre avis juridique qui décrit nos conditions d'utilisation du site Web.
En accédant à www.sernova.com (le «site Web»), vous acceptez les pratiques décrites dans la présente politique de confidentialité (la «politique»).
Cette politique s'applique à toutes les informations collectées via le site Web et / ou toute technique ou événement marketing associé.
Collecte d'informations
Les informations collectées se limitent aux informations que vous décidez de partager avec nous par le biais du service d’expédition de nouvelles, lorsque vous participez à un événement ou à des activités ou que vous vous intéressez à obtenir des informations sur Sernova Corp. comme nom, email, numéro de téléphone et informations de contact similaires. Ces informations sont stockées via MailChimp (veuillez vous reporter aux règles de confidentialité de MailChimp sur https://mailchimp.com/legal/privacy/).
Partage d'information
Sernova Corp. est l'unique propriétaire de toute information collectée sur le site Web. Nous ne vendons pas, ne partageons pas ou ne louons pas ces informations à des tiers.
Collecte d'informations routières et automatiques
Sernova Corp. gère les fichiers journaux du trafic sur www.sernova.com. Ces informations ne sont liées à aucune information personnelle que vous nous avez fournie. Les journaux sont utilisés pour gérer le trafic, identifier le contenu accédé et les besoins informatiques. Les informations consignées et collectées automatiquement ne sont pas limitées aux adresses IP et aux types de navigateur. Cette information ne révèle pas votre identité spécifique.
Cookies
Les cookies peuvent être utilisés pour vous offrir une expérience plus personnalisée. Le site Web peut utiliser des cookies pour rendre cette expérience plus conviviale lorsque vous revenez sur le site Web. Vous avez la possibilité à tout moment de refuser l'utilisation de cookies. Si vous choisissez de le faire, vous ne pourrez peut-être pas utiliser toutes les fonctionnalités du site Web. Vous pouvez également supprimer des fichiers de cookies à tout moment depuis votre ordinateur. Ces cookies peuvent inclure des cookies de première partie (tels que les cookies de Google Analytics).
Mises à jour
Cette politique est un document évolutif et peut être modifié ou mis à jour de temps à autre sans préavis. Nous vous encourageons à consulter la politique périodiquement.
Contact
Si vous avez des questions ou des commentaires sur notre politique, vous pouvez nous envoyer un courriel à info@sernova.com ou par téléphone au 1 (877) 299-4603 ou par courrier à
Sernova Corp.
700 Collip Circle, Suite 114
London, ON Canada N6G 4X8